The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

Table 1 Comparison of four- and five-period crossover designs for TQT studies leading to the same statistical power

	Typical four-period TQT design	New five-period TQT design
Placebo periods	1	2
Placebo sessions	40	60
Supratherapeutic dose sessions	40	30
Therapeutic dose sessions	40	30
Active control sessions	40	30
Total number of sessions	160	150

ISSN: 1475-2840